Viewing Study NCT03713632

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:28 PM
Ignite Modification Date: 2025-12-28 @ 12:11 AM
Study NCT ID: NCT03713632
Status: COMPLETED
Last Update Posted: 2024-10-09
First Post: 2018-10-18
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hidradenitis Suppurativa View
Keywords:

Keywords

Keyword Brief Keyword Text View
None acne inversa View
None Hidradenitis suppurativa View
None maladie de Verneuil View
None inflammatory disease View
None AIN457 View
None AIN457M View
None secukinumab View
None HS View
None lumps View
None skin View
None lesions View